Have Questions?

Global Headquarters

Tel: +44 (0)20 7377 0800
Fax: +44 (0)20 7349 5157

North America

Tel: 1-617-573-9450
Fax: 1-617-573-9542


Tel: +81 (0)80-1164-4754

Request a Demo

What our customers are saying

When I think of the future, I think of EvaluatePharma

Senior Director,
Global pharmaceutical company

Surveying Tomorrow’s BioPharma Landscape: The NASDAQ Biotech Index Up Close 2012

EvaluatePharma NASDAQ Biotech Index 2012



Download EvaluatePharma’s Surveying Tomorrow’s BioPharma Landscape: The NASDAQ Biotech Index Up Close providing investors and the life science community with indispensable insights into the trends driving the index.


The report reveals the diversity of the 117 companies listed on the index, along with insights about pipeline development and consensus revenue estimates - key highlights include:

  • Industry-Beating Sales Growth: compound annual sales growth of prescription drugs generated by companies in the NASDAQ Biotech Index is expected to reach 8.3% in the 2011-2018 period, well above the 3.1% forecasted for the pharmaceutical industry (EvaluatePharma World Preview 2018
  • Unexpected Product Winners: By 2018, the highest-selling drug of any NBI company is expected to be Celgene’s Revlimid, approved in 2006 to treat a rare cancer, Revlimid’s sales could top $6.7 billion
  • Pipeline Points to More Biologics; Growth of Oncology, Anti-Infectives and CNS products: NBI companies have nearly 700 drugs in clinical trials, with 67% of the pipeline focused on cancer, anti-infectives and central nervous system diseases

Register or Login to download The NASDAQ Biotech Index Up Close 2012